FY2018 EPS Estimates for Spark Therapeutics Inc (ONCE) Lifted by Analyst

Spark Therapeutics Inc (NASDAQ:ONCE) – Equities researchers at SunTrust Banks raised their FY2018 earnings per share estimates for shares of Spark Therapeutics in a research note issued on Wednesday, according to Zacks Investment Research. SunTrust Banks analyst E. Nash now forecasts that the biotechnology company will post earnings of ($5.38) per share for the year, up from their previous forecast of ($5.60). SunTrust Banks has a “Buy” rating and a $113.00 price objective on the stock. SunTrust Banks also issued estimates for Spark Therapeutics’ Q4 2018 earnings at ($1.09) EPS, FY2019 earnings at ($1.97) EPS, FY2020 earnings at $0.80 EPS and FY2021 earnings at $2.54 EPS.

A number of other equities research analysts have also commented on the company. Raymond James Financial set a $66.00 price target on Spark Therapeutics and gave the company a “buy” rating in a research report on Wednesday, January 3rd. Cantor Fitzgerald set a $105.00 target price on Spark Therapeutics and gave the company a “buy” rating in a research report on Wednesday, January 3rd. BMO Capital Markets set a $67.00 target price on Spark Therapeutics and gave the company a “buy” rating in a research report on Tuesday, January 2nd. Goldman Sachs Group lowered Spark Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the company from $106.00 to $58.00 in a research report on Thursday, December 14th. They noted that the move was a valuation call. Finally, Barclays restated a “buy” rating and set a $54.00 target price on shares of Spark Therapeutics in a research report on Wednesday, December 13th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $76.03.

Spark Therapeutics (NASDAQ ONCE) traded down $1.41 during midday trading on Monday, hitting $52.66. The company’s stock had a trading volume of 712,141 shares, compared to its average volume of 947,267. Spark Therapeutics has a 1 year low of $41.06 and a 1 year high of $91.75. The company has a market cap of $1,950.00 and a price-to-earnings ratio of -7.31.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.11). Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The company had revenue of $1.90 million during the quarter, compared to the consensus estimate of $1.40 million. During the same quarter last year, the firm posted ($1.07) EPS. The company’s quarterly revenue was up 45.8% on a year-over-year basis.

Several institutional investors have recently modified their holdings of the company. Cornerstone Capital Management Holdings LLC. raised its stake in shares of Spark Therapeutics by 3.2% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 11,089 shares of the biotechnology company’s stock worth $662,000 after purchasing an additional 342 shares during the last quarter. Ameritas Investment Partners Inc. raised its stake in shares of Spark Therapeutics by 23.6% in the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 389 shares during the last quarter. California Public Employees Retirement System raised its stake in shares of Spark Therapeutics by 2.1% in the second quarter. California Public Employees Retirement System now owns 39,100 shares of the biotechnology company’s stock worth $2,336,000 after purchasing an additional 800 shares during the last quarter. Great West Life Assurance Co. Can raised its stake in shares of Spark Therapeutics by 47.3% in the third quarter. Great West Life Assurance Co. Can now owns 3,939 shares of the biotechnology company’s stock worth $351,000 after purchasing an additional 1,264 shares during the last quarter. Finally, Legal & General Group Plc raised its stake in shares of Spark Therapeutics by 16.8% in the second quarter. Legal & General Group Plc now owns 8,931 shares of the biotechnology company’s stock worth $532,000 after purchasing an additional 1,286 shares during the last quarter. 94.91% of the stock is owned by hedge funds and other institutional investors.

In related news, insider Daniel Faga sold 6,000 shares of the company’s stock in a transaction that occurred on Friday, October 20th. The stock was sold at an average price of $79.95, for a total transaction of $479,700.00. Following the transaction, the insider now directly owns 6,000 shares of the company’s stock, valued at approximately $479,700. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Katherine A. High sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 28th. The stock was sold at an average price of $71.32, for a total value of $356,600.00. Following the transaction, the insider now directly owns 215,000 shares in the company, valued at $15,333,800. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 62,309 shares of company stock worth $4,621,085. 7.30% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This article was originally published by BBNS and is the property of of BBNS. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://baseballnewssource.com/markets/fy2018-earnings-forecast-for-spark-therapeutics-inc-once-issued-by-suntrust-banks/1817558.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.